GCGuillaume Courbon

Guillaume Courbon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guillaume Courbon has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Broken signals: when the mineralostat alters the cardiovascular system

    by Emily Akerman, Amélie Cifuentes, Guillaume Courbon

    Patients with kidney disease face a markedly increased risk of developing cardiovascular disease (CVD) which manifests in multiple forms, including: left ventricular hypertrophy, heart failure, atherosclerosis, and vascular inflammation, all of which are associated in clinical studies to well-characterized morbidity and mortality reported throughout disease progression. These patients also exhibit disturbances in mineral metabolism and in the network of signals that regulate mineral balance, that we collectively refer to as the “mineralostat.” This review aims to summarize the links between mineralostat alterations and its potential implications for the onset and progression of CVD, as disruptive signals are transmitted to the heart and vascular system. Over the past decade, studies using sophisticated preclinical models have identified new proteins and signaling pathways of the mineralostat as candidates contributing to CVD. Here, we discuss the pathophysiological conditions reported to disrupt the mineralostat, the hormones involved in mineral metabolism, and the minerals. We also summarize the mechanisms through which each of these factors may promote CVD, with attention to their relevance for patients. Graphical Abstract The alternative text for this image may have been generated using AI. A higher resolution version of the Graphical abstract is available as Supplementary information

  • Top Cited Papers
    Open Access

    Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis

    by Guillaume Courbon, Jane J. Thomas, Eduardo J. Duque, Dominik Kentrup, Jadeah Spindler, William Semancheck, Emily Tracey, Douglas E Vaughan, Wenhan Chang, John W.M. Creemers, et al.

    Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone produced by osteocytes. In iron deficiency anemia (IDA) and in chronic kidney disease (CKD), FGF23 is also produced by erythroid cells. Recent studies have suggested that rising circulating FGF23 is negatively associated with erythropoiesis in IDA and CKD. However, the distinct contributions of bone- and erythroid-produced FGF23 to anemia in IDA remain unclear. Using the conditional deletion of Fgf23 in osteocytes (Fgf23Dmp1-cKO) and in erythroid cells (Fgf23HbB-cKO) in mice fed a control (Ctr) or an iron deficient (ID) diet, we first determined that in ID, osteocytes and erythroid cells are distinct sources of circulating intact FGF23 (iFGF23) and FGF23 cleaved peptides, respectively. We further show that erythroid-specific deletion of Fgf23 corrected anemia in ID mice, and overexpression induced anemia in Ctr mice unlike osteocyte-specific deletion or overexpression of Fgf23. Importantly, erythroid-specific deletion of Furin (FurinHbB-cKO), the enzyme responsible for FGF23 cleavage, led to increased production of iFGF23 from erythroid cells and aggravated ID-induced anemia. iFGF23 also dose-dependently blocked the differentiation of erythroid progenitors in culture triggering mitochondrial dysfunction leading to impaired erythropoiesis. These effects were fully suppressed by co-treatment with an FGFR1 inhibitor. Finally, erythroid-specific deletion of Fgf23 in an animal model of progressive CKD prevented the development of anemia of CKD. In aggregate, our results show that erythroid-expressed FGF23 is a negative regulator of erythropoiesis that contributes to anemia via direct paracrine FGFR1 activation in erythroid precursors.


  • Etudes cinétiques de la perte osseuse au cours de l'inflammation articulaire chronique

    by Guillaume Courbon

    La polyarthrite rhumatoïde est un rhumatisme inflammatoire chronique qui s’accompagne d’une inflammation synoviale et d’une perte osseuse sous-chondrale. Ces travaux de thèse ont porté sur la perte osseuse précoce dans l’arthrite et les mécanismes osseux et inflammatoires associés. La perte osseuse systémique a été étudiée et mise en relation avec la perte osseuse locale. La preuve de concept d’une perte osseuse précoce a été obtenue dans plusieurs études. Cette perte prédisait la sévérité de l’arthrite et débutait avant l’observation clinique de l’inflammation articulaire. Elle se traduisait par des modifications de la microarchitecture de l’os cortical et trabéculaire. Les mécanismes associés impliquaient l’activation de la résorption osseuse mais également l’inhibition de la formation osseuse. Une perte osseuse systémique a aussi été détectée, corrélant avec la perte locale. Dans le modèle de souris avec expression chronique du tumor necrosis factor (TNF), la perte osseuse axiale résultait d’une augmentation de la résorption osseuse sans affecter l’activité des ostéoclastes, suggérant que l’inhibition du TNF expliquerait la ré-ossification dans les formes axiales de SpA. L’infection orale avec Porphyromonas gingivalis induisait en huit mois une arthrite à bas bruit chez le rat, en augmentant les anticorps anti-peptides citrullinés et la résorption osseuse. Sur le versant translationnel, deux candidats thérapeutiques de l’arthrite ont démontré un effet régulateur de la dégénérescence articulaire associé à un effet protecteur sur l’os sous-chondral. Les résultats obtenus renforcent le concept de perte osseuse précoce dans l’arthrite, avec l’implication rapide des voies de régulations du tissu osseux. Des stratégies de bloquage de la résorption et de l’inhibition de la formation osseuse pourraient ainsi être développées dans les rhumatismes inflammatoires chroniques et leur usage envisagé dès les premiers stades de maladie.

  • Open Access

    Site-specific inverse associations between FGF23 levels and marrow adiposity content at the proximal femur in post-menopausal women

    by Julien Paccou, Sammy Badr, Nassima Ramdane, Laetitia Michou, Guillaume Courbon, Romuald Mentaverri


  • Open Access

    FGF23: A player not only in bone diseases

    by Amélie Cifuentes, Zacharie Laskar-Marchesseau, Guillaume Courbon


  • Open Access

    Critical Review of Hearing Rehabilitation in Pediatric Oncology: Specific Considerations and Barriers

    by Guillaume Courbon, Laurie Lugnier, Johnnie K. Bass, Thomas E. Merchant, Thierry Morlet, Celine Richard

    Childhood cancer treatments, including chemotherapy, radiation therapy, and combined modalities, pose significant risks to auditory function due to their ototoxic effects. Cisplatin, a chemotherapeutic agent commonly used in pediatric oncology, causes dose-dependent irreversible sensorineural hearing loss by damaging the inner ear structures, primarily through the generation of reactive oxygen species and the activation of apoptotic pathways. Radiation therapy exacerbates these effects, contributing to both sensorineural and conductive hearing loss via mechanisms such as vascular injury, inflammation, and fibrosis. The severity of hearing loss is influenced by the treatment timing, the cumulative dose, patient age, genetics, and concurrent therapies. The damaging effects of chemotherapy and radiation extend beyond the cochlea, involving the surrounding temporal bone as well as multiple levels of the auditory pathway. While pediatric patients may be candidates for bone-anchored hearing devices or cochlear implants, the need for serial imaging and the potential for implant-related MRI artifacts can complicate the timing of hearing rehabilitation. Moreover, the impact on the subcortical and cortical auditory structures may further influence the rehabilitation outcomes. This scoping review lays the foundation for future clinical and research efforts focused on the development of comprehensive pediatric guidelines for hearing preservation, monitoring, and rehabilitation, while also fostering multidisciplinary collaboration.


  • Open Access

    Postischemic inactivation of HIF prolyl hydroxylases in endothelium promotes maladaptive kidney repair by inducing glycolysis

    by Ratnakar Tiwari, Rajni Sharma, Ganeshkumar Rajendran, Gabriella S. Borkowski, Si Young An, Michael Schonfeld, James O’SUllivan, Matthew J. Schipma, Yalu Zhou, Guillaume Courbon, et al.

    Ischemic acute kidney injury (AKI) is common in hospitalized patients and increases the risk for chronic kidney disease (CKD). Impaired endothelial cell (EC) functions are thought to contribute in AKI to CKD transition, but the underlying mechanisms remain unclear. Here, we identify a critical role for endothelial oxygen sensing prolyl hydroxylase domain (PHD) enzymes 1–3 in regulating postischemic kidney repair. In renal endothelium, we observed compartment-specific differences in the expression of the 3 PHD isoforms in both mice and humans. Postischemic concurrent inactivation of endothelial PHD1, PHD2, and PHD3 but not PHD2 alone promoted maladaptive kidney repair characterized by exacerbated tissue injury, fibrosis, and inflammation. scRNA-Seq analysis of the postischemic endothelial PHD1, PHD2, and PHD3-deficient (PHD TiEC ) kidney revealed an endothelial hypoxia and glycolysis-related gene signature, also observed in human kidneys with severe AKI. This metabolic program was coupled to upregulation of the SLC16A3 gene encoding the lactate exporter monocarboxylate transporter 4 (MCT4). Strikingly, treatment with the MCT4 inhibitor syrosingopine restored adaptive kidney repair in PHDTiEC mice. Mechanistically, MCT4 inhibition suppressed proinflammatory EC activation, reducing monocyte-EC interaction. Our findings suggest avenues for halting AKI to CKD transition based on selectively targeting the endothelial hypoxia-driven glycolysis/MCT4 axis.


  • Open Access

    FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice

    by Guillaume Courbon, Dominik Kentrup, Jane Joy Thomas, Xueyan Wang, Hao-Hsuan Tsai, Jadeah Spindler, John Von Drasek, Laura Mazudie Ndjonko, Marta Martinez-Calle, Sana Lynch, et al.

    Fibroblast growth factor 23 (FGF23) is a phosphate-regulating (Pi-regulating) hormone produced by bone. Hereditary hypophosphatemic disorders are associated with FGF23 excess, impaired skeletal growth, and osteomalacia. Blocking FGF23 became an effective therapeutic strategy in X-linked hypophosphatemia, but testing remains limited in autosomal recessive hypophosphatemic rickets (ARHR). This study investigates the effects of Pi repletion and bone-specific deletion of Fgf23 on bone and mineral metabolism in the dentin matrix protein 1–knockout ( Dmp1 KO ) mouse model of ARHR. At 12 weeks, Dmp1 KO mice showed increased serum FGF23 and parathyroid hormone levels, hypophosphatemia, impaired growth, rickets, and osteomalacia. Six weeks of dietary Pi supplementation exacerbated FGF23 production, hyperparathyroidism, renal Pi excretion, and osteomalacia. In contrast, osteocyte-specific deletion of Fgf23 resulted in a partial correction of FGF23 excess, which was sufficient to fully restore serum Pi levels but only partially corrected the bone phenotype. In vitro, we show that FGF23 directly impaired osteoprogenitors’ differentiation and that DMP1 deficiency contributed to impaired mineralization independent of FGF23 or Pi levels. In conclusion, FGF23-induced hypophosphatemia is only partially responsible for the bone defects observed in Dmp1 KO mice. Our data suggest that combined DMP1 repletion and FGF23 blockade could effectively correct ARHR-associated mineral and bone disorders.


  • Open Access

    Transcription factor HNF4α2 promotes osteogenesis and prevents bone abnormalities in mice with renal osteodystrophy

    by Marta Martinez-Calle, Guillaume Courbon, Bridget Hunt-Tobey, Connor Francis, Jadeah Spindler, Xueyan Wang, Luciene M. dos Reis, Carolina S.W. Martins, Isidro B. Salusky, Hartmut Malluche, et al.

    Renal osteodystrophy (ROD) is a disorder of bone metabolism that affects virtually all patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes including fractures, cardiovascular events, and death. In this study, we showed that hepatocyte nuclear factor 4α (HNF4α), a transcription factor mostly expressed in the liver, is also expressed in bone, and that osseous HNF4α expression was dramatically reduced in patients and mice with ROD. Osteoblast-specific deletion of Hnf4α resulted in impaired osteogenesis in cells and mice. Using multi-omics analyses of bones and cells lacking or overexpressing Hnf4α1 and Hnf4α2, we showed that HNF4α2 is the main osseous Hnf4α isoform that regulates osteogenesis, cell metabolism, and cell death. As a result, osteoblast-specific overexpression of Hnf4α2 prevented bone loss in mice with CKD. Our results showed that HNF4α2 is a transcriptional regulator of osteogenesis, implicated in the development of ROD.


  • Open Access

    Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation

    by Guillaume Courbon, Jane Joy Thomas, Marta Martinez Calle, Xueyan Wang, Jadeah Spindler, John Von Drasek, Bridget Hunt-Tobey, Rupal Mehta, Tamara Isakova, Wenhan Chang, et al.

    Inflammation leads to functional iron deficiency, by increasing the expression of the hepatic iron regulatory peptide, hepcidin. Inflammation also stimulates fibroblast growth factor 23 (FGF23) production by increasing both Fgf23 transcription and FGF23 cleavage, which paradoxically leads to excess in C-terminal FGF23 peptides (Cter-FGF23), rather than intact hormone (iFGF23). We determined that the major source of Cter-FGF23 are the osteocytes and investigated whether Cter-FGF23 peptides play a direct role in the regulation of hepcidin and iron metabolism in response to acute inflammation. Mice harboring an osteocyte-specific deletion of Fgf23 showed a ~90% reduction in Cter-FGF23 levels during acute inflammation. Reduction in Cter-FGF23 led to a further decrease in circulating iron in inflamed mice due to excessive hepcidin production. We observed similar results in mice showing impaired FGF23 cleavage due to osteocyte-specific deletion of Furin. We next showed that Cter-FGF23 peptides bind members of the bone morphogenic protein (BMP) family, BMP2 and BMP9, which are established inducers of hepcidin. Co-administration of Cter-FGF23 and BMP2 or BMP9 prevented the increase in Hamp mRNA and circulating hepcidin levels induced by BMP2/9, resulting in normal serum iron levels. Finally, injection of Cter-FGF23 in inflamed Fgf23KO mice and genetic overexpression of Cter-Fgf23 in WT mice also resulted in lower hepcidin and higher circulating iron levels. In conclusion, during inflammation, bone is the major source of Cter-FGF23 secretion and independently of iFGF23, Cter-FGF23 reduces BMP-induced hepcidin secretion in the liver.